Maravai Q2 adjusted EPS misses estimates

Maravai Lifesciences Holdings

11/08/2025 21:38

Overview

Maravai Q2 revenue falls 31.7% yr/yr, meeting analyst expectations, per LSEG data

Adjusted EPS and EBITDA miss analyst estimates, per LSEG data

Co earlier announced restructuring for $50 mln annualized cost savings

Outlook

Maravai withdraws 2025 revenue guidance amid leadership transition

Company expects positive adjusted EBITDA by second half 2026

Maravai targets $50 mln in annualized cost savings

Restructuring charges estimated at $8-9 mln in H2 2025

Result Drivers

REVENUE DECLINE - Nucleic Acid Production revenue fell 43.1% due to lack of high-volume CleanCap orders for vaccine programs

RESTRUCTURING - Co targets over $50 mln in annualized cost savings through labor, facilities, capex and productivity initiatives

BIOLOGICS SAFETY TESTING - Revenue grew 9.9% driven by demand for Host Cell Protein kits and MockV viral clearance kits

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Meet
$47.40 mln
$47.40 mln (12 Analysts)
Q2 Adjusted EPS
Miss
-$0.08
-$0.07 (11 Analysts)
Q2 EPS
-$0.27
Q2 Adjusted EBITDA
Miss
-$10.40 mln
-$8.39 mln (9 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Maravai LifeSciences Holdings Inc is $5.00, about 56% above its August 8 closing price of $2.20

Press Release: ID:nGNX38xcQh

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)